ScholarIQanswers from OpenAlex
AstraZeneca (Japan)
InstitutionResearch output, impact & collaborations
AstraZeneca (Japan) is a institution indexed in ScholarIQ from OpenAlex.
What is known about AstraZeneca (Japan)?
ScholarIQrecord summary
AstraZeneca (Japan) is a research organisation in Osaka, JP. OpenAlex records 1,877 works and 187,968 citations for it. 833 researchers list it as their most recent affiliation.
How many works does AstraZeneca (Japan) have?
ScholarIQindexed works
AstraZeneca (Japan) has 1,877 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does AstraZeneca (Japan) have?
ScholarIQcitation count
AstraZeneca (Japan) has 187,968 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at AstraZeneca (Japan)?
ScholarIQresearcher count
AstraZeneca (Japan) has 833 researchers in the ScholarIQ index.
What is the average h-index at AstraZeneca (Japan)?
ScholarIQavg h-index
AstraZeneca (Japan) has an average h-index of 51.8 in OpenAlex.
What is the ROR of AstraZeneca (Japan)?
ScholarIQror
The ROR for AstraZeneca (Japan) is on the source record.
What is the OpenAlex record for AstraZeneca (Japan)?
ScholarIQopenalex
The OpenAlex for AstraZeneca (Japan) is on the source record.
Who are the most-cited researchers behind AstraZeneca (Japan)?
ScholarIQtop researchers by citations
What are the most-cited papers on AstraZeneca (Japan)?
ScholarIQmost cited works
The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers
Pedram Razavi, Matthew T. Chang, Guotai Xu, Chaitanya Bandlamudi, Dara S. Ross, Neil Vasan, Yanyan Cai, Craig M. Bielski, Mark T.A. Donoghue, Philip Jonsson, Alexander Penson, Ronglai Shen, Fresia Pareja, Ritika Kundra, Sumit Middha, Michael L. Cheng, Ahmet Zehir, Cyriac Kandoth, Ruchi Patel, Kety Huberman, Lillian M. Smyth, Komal Jhaveri, Shanu Modi, Tiffany A. Traina, Chau T. Dang, Wen Zhang, Britta Weigelt, Bob T. Li, Marc Ladanyi, David M. Hyman, Nikolaus Schultz, Mark E. Robson, Clifford A. Hudis, Edi Brogi, Agnès Viale, Larry Norton, Maura N. Dickler, Michael F. Berger, Christine A. Iacobuzio–Donahue, Sarat Chandarlapaty, Maurizio Scaltriti, Jorge S. Reis‐Filho, David B. Solit, Barry S. Taylor, José Baselga
Ionic immune suppression within the tumour microenvironment limits T cell effector function
Robert Eil, Suman K. Vodnala, David Clever, Christopher A. Klebanoff, Madhusudhanan Sukumar, Jenny H. Pan, Douglas C. Palmer, Alena Gros, Tori N. Yamamoto, Shashank J. Patel, Geoffrey Guittard, Zhiya Yu, Valentina Carbonaro, Klaus Okkenhaug, David S. Schrump, W. Marston Linehan, Rahul Roychoudhuri, Nicholas P. Restifo
Non–Small Cell Lung Cancer, Version 6.2015
David S. Ettinger, Douglas E. Wood, Wallace Akerley, Lyudmila Bazhenova, Hossein Borghaei, David Ross Camidge, Richard T. Cheney, Lucian R. Chirieac, Thomas A. D’Amico, Todd L. Demmy, Thomas J. Dilling, M.C. Dobelbower, Ramaswamy Govindan, Frederic W. Grannis, Leora Horn, Thierry Jahan, Ritsuko Komaki, Lee M. Krug, Rudy P. Lackner, Michael Lanuti, Rogério Lilenbaum, Jules Lin, Billy W. Loo, Renato Martins, Gregory A. Otterson, Jyoti D. Patel, Katherine M.W. Pisters, Karen L. Reckamp, Gregory J. Riely, Eric Rohren, Steven E. Schild, Theresa A. Shapiro, Steven Swanson, Kurt W. Tauer, Stephen C. Yang, Kristina M. Gregory, Miranda Hughes
Discovery of a First-in-Class Receptor Interacting Protein 1 (RIP1) Kinase Specific Clinical Candidate (GSK2982772) for the Treatment of Inflammatory Diseases
Philip A. Harris, Scott B. Berger, Jae Uk Jeong, Rakesh Nagilla, Deepak Bandyopadhyay, Nino Campobasso, Carol A. Capriotti, Julie A. Cox, Lauren Dare, Xiaoyang Dong, Patrick M. Eidam, Joshua N. Finger, Sandra J. Hoffman, James Kang, Viera Kasparcova, Bryan W. King, Ruth Lehr, Yunfeng Lan, Lara K. Leister, John D. Lich, Thomas T. MacDonald, Nathan A. Miller, Michael T. Ouellette, Christina Pao, A. H. ABD EL RAHMAN, Michael Reilly, Alan R. Rendina, Elizabeth J. Rivera, Michelle C. Schaeffer, Clark A. Sehon, Robert R. Singhaus, Helen H. Sun, Barbara A. Swift, Rachel D. Totoritis, Anna Vossenkämper, Paris Ward, David D. Wisnoski, Daohua Zhang, Robert W. Marquis, Peter J. Gough, John Bertin
PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor–positive breast cancer
Ana Bosch, Zhiqiang Li, Anna Bergamaschi, Haley Ellis, Eneda Toska, Aleix Prat, Jessica J. Tao, Daniel E. Spratt, Nerissa T. Viola, Pau Castel, Gerard Minuesa, Natasha Morse, Jordi Rodón, Yasir H. Ibrahim, Javier Cortés, José Manuel Pérez-García, Patricia Galván, Judit Grueso, Marta Guzmán, John A. Katzenellenbogen, Michael G. Kharas, Jason S. Lewis, Maura N. Dickler, Violeta Serra, Neal Rosen, Sarat Chandarlapaty, Maurizio Scaltriti, José Baselga
How much of the research on AstraZeneca (Japan) is open access?
ScholarIQopen access share
75%OPEN ACCESS